Clinuvel Pharmaceuticals Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Clinuvel Pharmaceuticals Limited generated cash of $37,053,882, which is more than the previous year. Cash used in financing activities reached the amount of -$3,571,807 last year. Net change in cash is therefore $3,307,730.
Cash Flow
| 2015 | -4.52M | -10.69K | 222.7K |
|---|---|---|---|
| 2016 | -5.03M | -98.05K | 8.38M |
| 2017 | 9.91M | -67.47K | 85.08K |
| 2018 | 11.69M | -75.12K | 0 |
| 2019 | 18.45M | -257.61K | -1.03M |
| 2020 | 14.18M | -888.82K | -1.48M |
| 2021 | 19.26M | -854.32K | -1.47M |
| 2022 | 39.87M | -434.43K | -1.50M |
| 2023 | 36.91M | -1.02M | -2.24M |
| 2024 | 37.05M | -29.03M | -3.57M |
CLVLY Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 31.89M | 27.40M | 37.14M | 25.65M | 25.74M | 36.19M | 23.75M | 13.84M | 10.57M | 14.62M |
Operating activities | ||||||||||
Net income | 0 | 30.60M | 20.87M | 24.72M | 15.05M | 18.13M | 13.22M | 7.18M | -3.12M | -10.39M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 789.40K | 757.82K | 861.43K | 446.12K | 214.16K | 44.54K | 53.13K | 25.52K | 26.53K |
Stock-based compensation expense | 0 | 8.98M | 6.12M | 2.60M | 1.65M | 139.93K | 0 | 395.36K | 1.67M | 5.67M |
| Deferred income tax benefit | 0 | 8.98M | 6.12M | 2.60M | 1.65M | 139.93K | 0 | 395.36K | 1.67M | 5.67M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -6.01M | -113.41K | -9.47M | -2.45M | 934.05K | -1.85M | 1.58M | -2.86M | -356.82K |
Inventories | 0 | -7.68M | 1.35M | -1.89M | 848.17K | -1.49M | 600.32K | -159.44K | -245.02K | -837.13K |
Accounts payable | -648.31K | 4.51M | -1.56M | -20.44K | 2.66M | 1.51M | 205.68K | 729.71K | -297.40K | 0 |
Cash generated by operating activities | 37.05M | 36.91M | 39.87M | 19.26M | 14.18M | 18.45M | 11.69M | 9.91M | -5.03M | -4.52M |
Investing activities | ||||||||||
Purchases Of Investments | -23.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -5.57M | -1.02M | -434.43K | -854.32K | -888.82K | -257.61K | -75.12K | -67.47K | -98.05K | -12.09K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -29.03M | -1.02M | -434.43K | -854.32K | -888.82K | -257.61K | -75.12K | -67.47K | -98.05K | -10.69K |
Financing activities | ||||||||||
Common Stock Issued | 4.15M | 0 | 0 | 0 | 0 | 0 | 0 | 85.08K | 8.29M | 250K |
Payments for dividends | -2.47M | -1.97M | -1.23M | -1.23M | -1.22M | -957.16K | 0 | 0 | 0 | 0 |
Repurchases of common stock | -4.90M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -36.05K | -27.3K |
Repayments of term debt | 0 | 0 | 0 | -200.28K | -243.34K | -69.62K | 0 | 0 | 0 | 0 |
Cash used in financing activities | -3.57M | -2.24M | -1.50M | -1.47M | -1.48M | -1.03M | 0 | 85.08K | 8.38M | 222.7K |
Net Change In Cash | 3.30M | -3.54M | -9.73M | 11.48M | -91.81K | 18.07M | 12.44M | 9.90M | 3.27M | -4.05M |
Cash at end of period | 35.20M | 23.86M | 27.40M | 37.14M | 25.65M | 54.26M | 36.19M | 23.75M | 13.84M | 10.57M |